VERVE-102: A One-Shot CRISPR Gene Edit for LDL Cholesterol

Picture a hospital recliner in Boston, an IV line threaded into a patient's arm, and a single bag of pale fluid dripping into a vein. The infusion takes a few hours. The patient goes home. The bag contains lipid nanoparticles carrying instructions, not to a drug, but to a patient's own liver cells: rewrite one letter of DNA in the PCSK9 gene, switch it off, and never make the protein again. That single dose, given on 12 November 2025, was the first time VERVE-102 had been administered to a patient in the United States [1].

What VERVE-102 actually does

The drug is Verve Therapeutics' second-generation in vivo CRISPR base editor, now owned by Eli Lilly, which acquired Verve in 2025 for about $1.6 billion [2]. A base editor is a tool that swaps a single chemical letter of DNA, an adenine for a guanine, without cutting the double helix. That precision matters, because earlier CRISPR systems worked like molecular scissors and could leave ragged ends. Base editing is closer to a pencil with a very fine eraser.

VERVE-102's target is the PCSK9 gene, which makes a protein that tells the liver to clear LDL receptors from the surface of cells. Knock out PCSK9 and the liver keeps pulling LDL cholesterol out of the blood. People born with naturally broken PCSK9 genes have strikingly low LDL and almost no heart disease. Verve's bet is that mimicking that natural experiment, on purpose, in adults, will do the same.

The drug is delivered as a single intravenous infusion, packaged in lipid nanoparticles, the same kind of fat bubble that carried the mRNA in COVID vaccines. Once there, the bubbles ferry the base editor to liver cells, where it does its work, then disappear. Verve describes the result as a one-and-done therapy, with the company modeling durability on two to three years of follow-up in the predecessor drug, VERVE-101.

The Heart-1 numbers

The early data are striking. On the same day as the first US dose, Verve and Lilly reported mean LDL cholesterol reductions of 53 to 69 percent across dose cohorts in the Heart-1 Phase 1b trial [1]. The highest dose cohort, in Lilly's release, hit 69 percent, with blood PCSK9 protein falling by 88 percent [2]. These are early readouts, not the final word, but they sit within the same range that current injectable PCSK9 drugs achieve only with fortnightly shots.

The trial enrols patients with heterozygous familial hypercholesterolemia, an inherited form of very high cholesterol, and people with established atherosclerotic cardiovascular disease, the hardening and narrowing of arteries that causes heart attacks. Both groups are notoriously hard to treat with statins alone. Real-world adherence to statins sits around 50 percent, which is one of the structural problems a one-shot gene edit would solve.

A rocky road

It has not all been smooth. The predecessor drug, VERVE-101, was paused in 2024 after a New Zealand patient suffered a heart attack about five weeks after dosing. An independent committee classified the event as possibly drug-related [3]. Share prices fell sharply, and the field had to reckon with the risk. Verve's response was to design VERVE-102 with a more precise base editor, intended to reduce off-target editing in the liver. Low-level off-target editing had been observed in the original New England Journal of Medicine publication of the VERVE-101 first-in-human study, which showed durable LDL-C reductions of 39 to 48 percent at six months in ten HeFH patients [4]. No serious cardiac events have been reported so far in Heart-1 dosing, though patient numbers remain small.

This matters because in vivo gene editing is a young field, and a single serious adverse event can reshape an entire programme. The pause did not kill the science. It changed it.

The Australian picture

For Australian readers, the question is when, and whether, a drug like VERVE-102 would ever be available locally. Cardiovascular disease causes about a quarter of all deaths in Australia, and roughly 1.5 million adults live with high cholesterol, according to the Heart Foundation [6]. Familial hypercholesterolemia is rare but not vanishing, affecting about one in 250 people, and the people who have it often need help beyond a daily statin.

Current PCSK9 drugs, including evolocumab and alirocumab, are already listed on the Pharmaceutical Benefits Scheme for patients who do not reach target LDL on statins and ezetimibe. These are monoclonal antibodies, lab-made proteins that bind and neutralise PCSK9 in the blood. They cut LDL by 55 to 60 percent, but they require a subcutaneous injection every two weeks, indefinitely [7]. Inclisiran, a small interfering RNA, is also PBS-listed and works twice a year, but it is still an ongoing treatment. None of these is one-and-done.

VERVE-102 is not yet approved by the US Food and Drug Administration, and there is no Therapeutic Goods Administration application on foot. The TGA typically follows the FDA by 6 to 12 months, and a PBS listing would add more time. If approvals come on schedule, an Australian patient with familial hypercholesterolemia or premature coronary disease might see VERVE-102 by 2028, though pricing will be the real gatekeeper.

Why this matters

The promise of VERVE-102 is not just a better number on a blood test. It is the possibility of a single intervention that removes the daily negotiation with a pill bottle. For people with familial hypercholesterolemia, who already know their LDL will climb the moment they stop a statin, the option of a one-shot therapy is a structural shift. For health systems, it is a high upfront cost traded for a long tail of prevented heart attacks and strokes.

The risks are real. Gene editing is not reversible. The VERVE-101 heart attack is a reminder that the field is moving faster than the long-term safety data. Verve's newer base editor is more precise, but the patient cohorts are still small and the follow-up is still measured in years, not decades.

For now, the picture is a familiar one: a striking early signal, a rocky past, and a future that depends on the next thousand patients. The Boston recliner, the IV bag, the rewritable liver: these are the small, careful beginnings of a therapy that, if it works, would redraw the daily life of cardiovascular care.